Consolidation

(Image: Getty/kritchanut)

Guest column

M&A in the CRO industry: The Good, The Bad, and The Ugly

By Matthew Barrows, senior business consultant

M&A is a huge part of the CRO space. Inorganic growth has long been the go-to strategy for any CRO and we’re never surprised to see this month’s latest deal. However, I’d like to challenge the idea that this is always the best way to grow a CRO business.

(Image: Getty/martince2)

SCOPE 2018

A CRO monopoly? Sponsors frustrated with lack of options

By Melissa Fassbender

With fewer global mid-sized contract research organizations (CRO) through consolidation, some stakeholders are expressing concern that the industry could become a monopoly – “we may be getting there,” one expert said.

GettyImages/maxsattana

Charles River to buy MPI Research for $800m

By Flora Southey

Charles River Laboratories International says it is en route to ‘double its size in five years’ with the acquisition of non-clinical CRO MPI Research.

(Image: iStock/manaemedia)

INC Research/inVentiv now Syneos Health

By Melissa Fassbender

INC Research/inVentiv Health is starting the new year with a rebrand after merging to create one of the largest biopharmaceutical outsourcing providers in 2017.

GettyImages/dima_sidelnikov

Flexible, agile, niche: How small-sized CROs compete

By Flora Southey

Niche, small-scale CROs can stand their own – despite a predicted increase in consolidation among small-sized contract services firms – says Clinical Trial Consultants (CTC) and data-focused Quanticate.

Top CRO M&A activity of 2016

Top CRO M&A activity of 2016

By Melissa Fassbender

As 2016 comes to a close, Outsourcing-Pharma.com looks back at some of the major mergers and acquisitions from the past year.

(Image: iStock/travellinglight)

Evotec completes Cyprotex acquisition

By Melissa Fassbender

Evotec AG has completed its previously announced acquisition of the preclinical contract research organization (CRO), Cyrotex.

The deal is the latest in a string of private equity investment into the market. (Image: iStock/jansucko)

Private equity snags another CRO, Premier Research

By Melissa Fassbender

Premier Research has become the most recent contract research organization (CRO) to receive funding from private equity as the industry looks for "like-minded" partners for the long run.

Icon’s acquisition of Clinical Research Management (ClinicalRM) expands its presence in the government sponsored research market. (Image: iStock/BernardaSv)

ICON completes ClinicalRM acquisition

By Melissa Fassbender

The acquisition, which was announced in June of this year, has been completed, expanding the company’s reach into government sponsored research.

The transaction is expected to close in the fourth quarter of 2016. (Image: iStock/pichet_w)

Bioclinica acquired by private equity firm

By Melissa Fassbender

The international private equity firm, Cinven, is set to purchase Bioclinica, marking the company’s latest in a series of purchases as industry consolidation continues.

ABC Laboratories was initially acquired in July 2015. (Image: iStock/Gajus)

ABC Labs unified under newly formed EAG Laboratories

By Melissa Fassbender

The independent lab network has combined 11 of its brands, including ABC Laboratories, to reside under a single company in order to “leverage cross functional capabilities,” says CEO.

The acquisition is the latest in a series. (Image: iStock)

Charles River acquires analytical CRO

By Melissa Fassbender

Charles River Laboratories has acquired Blue Stream Laboratories, expanding the company’s biologic and biosimilar development capabilities.

Partners Group plans to work with PCI's management team to add more specialized offerings. (Image: iStock/RomoloTavani)

PCI Pharma Services' new owners focused on growth

By Melissa Fassbender

Partners Group, a private markets investment manager, has agreed to acquire global pharmaceutical services provider PCI Pharma Services citing “trends towards outsourcing.”

Charles River will continue to broaden its early stage portfolio. (Image: iStock)

Charles River: 2016 to be 'robust year'

By Melissa Fassbender

After reporting a successful FY16, Charles River expects a successful new year driven by customer demand and enhanced strategic partnerships.

Follow us

Products

View more

Webinars